Finding 1057582 (2022-016)

Significant Deficiency
Requirement
B
Questioned Costs
-
Year
2022
Accepted
2024-08-15
Audit: 317252
Organization: Unity Health Care, Inc. (MD)
Auditor: Bdo USA PC

AI Summary

  • Core Issue: The Corporation lacks documentation for indirect cost pools, making it unclear if costs charged to Federal awards meet compliance requirements.
  • Impacted Requirements: This situation violates 2 CFR 200.303(a) and Appendix IV to Part 200 Section B.2(b) regarding effective internal controls and allowable costs.
  • Recommended Follow-up: The Corporation should establish formal processes and policies to ensure compliance with indirect cost allowability requirements.

Finding Text

Criteria: 2 CFR 200.303(a) establishes that the auditee must establish and maintain effective internal control over the Federal award that provides assurance that the entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Additionally, 2 CFR Appendix IV to Part 200 Section B.2(b) requires that both the direct costs and the indirect costs must exclude capital expenditures and unallowable costs. Per Compliance Supplement, these indirect costs must conform to the allowability of cost provisions in 2 CFR Part 200, Subpart E or award agreement. Condition: During our testing of indirect costs, we noted that the Corporation charges the Federally approved rate of 28.7% on specific grant awards based on direct salaries and wages. However, the Corporation did not maintain supporting indirect cost pools and related documentation. Cause: The Corporation did not have formal process and policies to demonstrate adherence to the allowability requirements of indirect costs in accordance with 2 CFR Appendix IV to Part 200 Section B.2(b). Effect or Potential Effect: We were unable to determine whether indirect costs charged to Federal awards conform to the allowability of cost provisions in 2 CFR Part 200, Subpart E or award agreement. Allowable costs incurred by the Corporation exceeded the amount of approved grant funding, therefore no questioned costs are reported. Questioned costs: Unknown Context: Management was not able to provide sufficient and appropriate evidence that the reported indirect costs conformed to the allowability of cost provisions in 2 CFR Part 200, Subpart E or award agreement. Repeat finding: No Recommendation: We recommend the Corporation develop and incorporate internal controls and policies to demonstrate adherence to the allowability requirements of indirect costs in accordance with 2 CFR Appendix IV to Part 200 Section B.2(b). View of Responsible Officials: Due to turnover of several key financial executives and personnel, the Corporation did not maintain any supporting indirect cost pools and related documentation.

Categories

Allowable Costs / Cost Principles

Other Findings in this Audit

  • 481113 2022-004
    Material Weakness Repeat
  • 481114 2022-005
    Material Weakness Repeat
  • 481115 2022-006
    Material Weakness Repeat
  • 481116 2022-007
    Significant Deficiency Repeat
  • 481117 2022-009
    Material Weakness Repeat
  • 481118 2022-010
    Significant Deficiency Repeat
  • 481119 2022-011
    Significant Deficiency Repeat
  • 481120 2022-004
    Material Weakness Repeat
  • 481121 2022-005
    Material Weakness Repeat
  • 481122 2022-006
    Material Weakness Repeat
  • 481123 2022-007
    Significant Deficiency Repeat
  • 481124 2022-009
    Material Weakness Repeat
  • 481125 2022-010
    Significant Deficiency Repeat
  • 481126 2022-011
    Significant Deficiency Repeat
  • 481127 2022-004
    Material Weakness Repeat
  • 481128 2022-005
    Material Weakness Repeat
  • 481129 2022-006
    Material Weakness Repeat
  • 481130 2022-007
    Significant Deficiency Repeat
  • 481131 2022-012
    Significant Deficiency
  • 481132 2022-013
    Significant Deficiency
  • 481133 2022-016
    Significant Deficiency
  • 481134 2022-017
    Significant Deficiency
  • 481135 2022-004
    Material Weakness Repeat
  • 481136 2022-005
    Material Weakness Repeat
  • 481137 2022-006
    Material Weakness Repeat
  • 481138 2022-008
    Significant Deficiency Repeat
  • 481139 2022-009
    Material Weakness Repeat
  • 481140 2022-016
    Significant Deficiency
  • 481141 2022-004
    Material Weakness Repeat
  • 481142 2022-005
    Material Weakness Repeat
  • 481143 2022-006
    Material Weakness Repeat
  • 481144 2022-007
    Significant Deficiency Repeat
  • 481145 2022-016
    Significant Deficiency
  • 481146 2022-004
    Material Weakness Repeat
  • 481147 2022-005
    Material Weakness Repeat
  • 481148 2022-006
    Material Weakness Repeat
  • 481149 2022-010
    Significant Deficiency Repeat
  • 481150 2022-014
    Material Weakness
  • 481151 2022-015
    Significant Deficiency
  • 481152 2022-016
    Significant Deficiency
  • 1057555 2022-004
    Material Weakness Repeat
  • 1057556 2022-005
    Material Weakness Repeat
  • 1057557 2022-006
    Material Weakness Repeat
  • 1057558 2022-007
    Significant Deficiency Repeat
  • 1057559 2022-009
    Material Weakness Repeat
  • 1057560 2022-010
    Significant Deficiency Repeat
  • 1057561 2022-011
    Significant Deficiency Repeat
  • 1057562 2022-004
    Material Weakness Repeat
  • 1057563 2022-005
    Material Weakness Repeat
  • 1057564 2022-006
    Material Weakness Repeat
  • 1057565 2022-007
    Significant Deficiency Repeat
  • 1057566 2022-009
    Material Weakness Repeat
  • 1057567 2022-010
    Significant Deficiency Repeat
  • 1057568 2022-011
    Significant Deficiency Repeat
  • 1057569 2022-004
    Material Weakness Repeat
  • 1057570 2022-005
    Material Weakness Repeat
  • 1057571 2022-006
    Material Weakness Repeat
  • 1057572 2022-007
    Significant Deficiency Repeat
  • 1057573 2022-012
    Significant Deficiency
  • 1057574 2022-013
    Significant Deficiency
  • 1057575 2022-016
    Significant Deficiency
  • 1057576 2022-017
    Significant Deficiency
  • 1057577 2022-004
    Material Weakness Repeat
  • 1057578 2022-005
    Material Weakness Repeat
  • 1057579 2022-006
    Material Weakness Repeat
  • 1057580 2022-008
    Significant Deficiency Repeat
  • 1057581 2022-009
    Material Weakness Repeat
  • 1057583 2022-004
    Material Weakness Repeat
  • 1057584 2022-005
    Material Weakness Repeat
  • 1057585 2022-006
    Material Weakness Repeat
  • 1057586 2022-007
    Significant Deficiency Repeat
  • 1057587 2022-016
    Significant Deficiency
  • 1057588 2022-004
    Material Weakness Repeat
  • 1057589 2022-005
    Material Weakness Repeat
  • 1057590 2022-006
    Material Weakness Repeat
  • 1057591 2022-010
    Significant Deficiency Repeat
  • 1057592 2022-014
    Material Weakness
  • 1057593 2022-015
    Significant Deficiency
  • 1057594 2022-016
    Significant Deficiency

Programs in Audit

ALN Program Name Expenditures
93.224 Consolidated Health Centers (community Health Centers, Migrant Health Centers, Health Care for the Homeless, and Public Housing Primary Care) $4.41M
93.788 Opioid Str $1.46M
93.217 Family Planning_services $1.34M
10.557 Special Supplemental Nutrition Program for Women, Infants, and Children $1.29M
93.914 Hiv Emergency Relief Project Grants $898,253
93.918 Grants to Provide Outpatient Early Intervention Services with Respect to Hiv Disease $584,947
93.837 Cardiovascular Diseases Research $402,416
93.917 Hiv Care Formula Grants $367,131
93.426 Improving the Health of Americans Through Prevention and Management of Diabetes and Heart Disease and Stroke $178,078
93.994 Maternal and Child Health Services Block Grant to the States $169,521
93.268 Immunization Cooperative Agreements $167,318
93.236 Grants to States to Support Oral Health Workforce Activities $104,190
93.898 Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations $81,214
93.526 Affordable Care Act (aca) Grants for Capital Development in Health Centers $77,935
93.889 National Bioterrorism Hospital Preparedness Program $33,398
93.279 Drug Abuse and Addiction Research Programs $31,446
93.297 Teenage Pregnancy Prevention Program $14,271
93.855 Allergy, Immunology and Transplantation Research $1,571